San Francisco experts say payer step edits and weak biologic follow-up slow atopic dermatitis care and point to pharmacy ...
In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ...
FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small ...
Panelists concurred that precision medicine can serve to exacerbate care inequality if not everyone can access these therapeutics.
IL-23 inhibitors linked to lower psoriatic arthritis risk than JAK inhibitors, and IL-17 inhibitors showed higher risk.
Once weekly tirzepatide significantly reduces body mass index in adolescents with obesity compared with placebo.
Rural patients with HFrEF had lower mortality when treated at urban hospitals but higher early mortality than urban patients ...
Building a third-line treatment framework starts with molecular profile and available targeted options, but ultimately rests ...
Most eligible patients stand to benefit from twice-yearly dosing, though candidate selection still matters, and clinical trial data reveal no new safety signals relative to more frequently dosed ...
With multiple oral JAK inhibitors approaching approval, sequencing decisions and adverse-event management are becoming urgent clinical questions. Dr. Desai and Dr. Hamzavi outline how they select ...